19064-26-7

Basic information

• Product Name: N1-(2,6-DIFLUOROPHENYL)-2-CHLOROACETAMIDE
• Synonyms: BUTTPARK 30\07-55;AKOS BBS-00006512;AKOS UB-20203;2-CHLORO-N-(2,6-DIFLUOROPHENYL)ACETAMIDE;OTAVA-BB BB7020410088;N1-(2,6-DIFLUOROPHENYL)-2-CHLOROACETAMIDE
• CAS NO: 19064-26-7
• Molecular Formula: C₈H₆ClF₂NO
• Molecular Weight: 205.59
• Mol File: 19064-26-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 302.5°C at 760 mmHg
• Flash Point: 136.8°C
• Appearance: /
• Density: 1.444g/cm³
• Vapor Pressure: 0.000983mmHg at 25°C
• Refractive Index: 1.55
• CAS DataBase Reference: N1-(2,6-DIFLUOROPHENYL)-2-CHLOROACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N1-(2,6-DIFLUOROPHENYL)-2-CHLOROACETAMIDE(19064-26-7)
• EPA Substance Registry System: N1-(2,6-DIFLUOROPHENYL)-2-CHLOROACETAMIDE(19064-26-7)

Safety Data

• Hazardous Substances Data: 19064-26-7(Hazardous Substances Data)

Usage

General Description

N1-(2,6-Difluorophenyl)-2-chloroacetamide, also known as DFPCA, is a chemical compound with the molecular formula C8H6ClF2NO. It is a synthetic organic molecule that belongs to the class of acetamides. DFPCA is commonly used in the pharmaceutical industry as an intermediate in the synthesis of various drugs and pharmaceutical compounds. It has been studied for its potential pharmacological properties, including its antifungal and antibacterial activities. In addition, DFPCA has also been investigated for its potential use as a precursor in the development of new therapeutic agents with enhanced efficacy and safety profiles.

InChI:InChI=1/C8H6ClF2NO/c9-4-7(13)12-8-5(10)2-1-3-6(8)11/h1-3H,4H2,(H,12,13)

Upstream product

• 5509-65-9 2,6-difluoroaniline 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 1017590-13-4 C₁₂H₁₂F₂N₂O₂S 
• 1236306-36-7 N-(2,6-difluorophenyl)-2-(4-(4-benzylphthalazin-1-yl)piperazin-1-yl)acetamide 
• 1236306-23-2 N-(2,6-difluorophenyl)-2-(4-(4-(pyridin-4-ylmethyl)phthalazin-1-yl)piperazin-1-yl)acetamide 

Relevant articles and documents

Synthesis and Biological Evaluation of Dithiobisacetamides as Novel Urease Inhibitors

Thirty-eight disulfides containing N-arylacetamide were designed and synthesized in an effort to develop novel urease inhibitors. Biological evaluation revealed that some of the synthetic compounds exhibited strong inhibitory potency against both cell-free urease and urease in intact cell with low cytotoxicity to mammalian cells even at concentration up to 250 μM. Of note, 2,2′-dithiobis(N-(2-fluorophenyl)acetamide) (d7), 2,2′-dithiobis(N-(3,5-difluorophenyl)acetamide) (d24), and 2,2′-dithiobis(N-(3-fluorophenyl)acetamide) (d8) were here identified as the most active inhibitors with IC50 of 0.074, 0.44, and 0.81 μM, showing 32- to 355-fold higher potency than the positive control acetohydroxamic acid. These disulfides were confirmed to bind urease without covalent modification of the cysteine residue and to inhibit urease reversibly with a mixed inhibition mechanism. They also showed very good anti-Helicobacter pylori activities with d8 showing a comparable potency to the clinical used drug amoxicillin. The impressive in vitro biological profile indicated their immense potential as therapeutic agents to tackle H. pylori caused infections.

Synthesis and antitumor activities of novel 1,4-disubstituted phthalazine derivatives

In an attempt to develop potent and selective antitumor agents,a series of novel 1,4-disubstituted phthalazine derivatives was designed and synthesized. All the prepared compounds were screened for their cytotoxic activities against A549,HT-29 and MDA-MB-231 cell lines in vitro. Among them,seven compounds (7a7e,7j and 7i) displayed excellent selectivity for MDA-MB-231 cells with IC50 values in the nM range,a desirable range for pharmacological testing. The most promising compound,7a (IC50 = 3.79 μ M,2.32 μ M,0.84 nM),was 5.6-,10.8-and 6.9 × 104-times more active than PTK-787 (IC50 = 21.16 μ M,22.11 μ M,57.72 μ M),respectively.